
One of the news that has attracted the attention of the whole world for the importance it is expected to have in helping cancer patients in the future, is the vaccine against lung cancer and the start of its testing in patients.
But how does this vaccine work?
This is the first cancer vaccine that uses messenger RNA (mRNA).
Immunotherapy for non-small cell lung cancer (NSCLC) uses messenger RNA (mRNA) to target cancerous tumor cells.
This helps the immune system recognize and fight cancer cells that have already been targeted.
The vaccine is designed to specifically enhance immune responses against targets, which reduces the risk of toxicity to healthy, non-cancerous cells. This is also the difference from chemotherapy, a therapy widely used to treat this disease.
Chemotherapy, in addition to targeting cancer cells, often affects healthy cells as well.
The vaccine also aims to prevent the creation of new cancer cells.
What is expected to happen after the first phase of testing?
As a phase one study, this trial will determine the safety of the BNT116 vaccine.
If the first phase of testing proves successful, researchers usually move on to a second phase, which will look at effectiveness and usually involve a larger number of patients. A phase III trial is larger still and usually compares a new treatment with the standard treatment. Experts say they hope this vaccine will eventually become the standard of care worldwide.